Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease

Figures & data

Figure 1 Skin photographs and chest images from an anti-MDA5-positive ADM patient with early-stage ILD before extended-release Tof treatment. Reddish-purple discoloration around the eyelids with swelling (heliotrope rash) (A) and erythematous area on the upper back and posterior neck (shawl sign) (B). Bilateral diffuse infiltration with ground-glass opacity (GGO) on high-resolution chest CT (C and D) at the diagnosis of ILD. Arrows indicate the GGO infiltration.

Figure 2 Skin photographs and chest images from an anti-MDA5-positive ADM patient with early-stage ILD after extended-release Tof treatment. Resolved heliotrope rash (A) and shawl sign (B). Resolved bilateral diffuse infiltration with GGO on high-resolution chest CT (C and D).